← All trials
NCT05116475
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 31, 2022
- Primary completion
- Feb 28, 2026
- Completion date
- Feb 28, 2027
- First posted
- Nov 11, 2021
- Last posted
- Nov 11, 2021
- Enrollment
- 152
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie (ARTIC)Lead sponsor
- BayerCollaborator
- University Hospital, ToursOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.